Shelley Hall

Shelley Hall

Auto-generated profile, based on publicly available information

Shelley Hall

Baylor University Medical Center, Dallas, Texas, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
HCHannah Copeland
Hannah Copeland
IKIvan Knezevic
Ivan Knezevic
DBDavid A. A Baran
David A. A Baran
VRVivek Rao
Vivek Rao
MPMichael Pham
Michael Pham
SHShelley A. Hall
Shelley A. Hall

2 February 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JKJon Kobashigawa
Jon Kobashigawa
DDDarshana M. Dadhania
Darshana M. Dadhania
MFMaryjane Farr
Maryjane Farr
WTW. H. Wilson Tang
W. H. Wilson Tang
ABArvind Bhimaraj
Arvind Bhimaraj
TPThe Consensus Conference Participants
The Consensus Conference Participants
Simultaneous heart‐kidney transplant (sHK) has enabled the successful transplantation of patients with end‐stage heart disease and concomitant kidney disease, with non‐inferior outcomes to heart transplant (HT) alone. The decision for sHK is challenged by difficulties in differentiating those patients with a significant component of reversible kidney injury due to cardiorenal syndrome who may recover kidney function after HT, from those with intrinsic advanced kidney disease who would benefit most from sHK. A consensus conference on sHK took place on June 1, 2019 in Boston, Massachusetts. The conference represented a collaborative effort by experts in cardiothoracic and kidney transplantation from centers across the United States to explore the development of guidelines for the interdisciplinary criteria for kidney transplantation in the sHK candidate, to evaluate the current allocation of kidneys to follow the heart for sHK, and to recommend standardized care for the management of sHK recipients. The conference served as a forum to unify criteria between the different specialties and to forge a pathway for patients who may need dual organ transplantation. Due to the continuing shortage of available donor organs, ethical problems related to multi‐organ transplantation were also debated. The findings and consensus statements are presented.

31 March 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
MIManhal J. Izzy
Manhal J. Izzy
BFBrett E. Fortune
Brett E. Fortune
MSMarina Serper
Marina Serper
NBNicole Bhave
Nicole Bhave
ADAndrew Delemos
Andrew Delemos
LVLisa B. VanWagner
Lisa B. VanWagner
Cardiac diseases are one of the most common causes of morbidity and mortality following liver transplantation (LT). Prior studies have shown that cardiac diseases affect close to one-third of liver transplant recipients (LTRs) long term and that their incidence has been on the rise. This rise is expected to continue as more patients with advanced age and/or non-alcoholic steatohepatitis undergo LT. In view of the increasing disease burden, a multidisciplinary initiative was developed to critically review the existing literature (between January 1, 1990 and March 17, 2021) surrounding epidemiology, risk assessment, and risk mitigation of coronary heart disease, arrhythmia, heart failure, and valvular heart disease and formulate practice-based recommendations accordingly. In this review, the expert panel emphasizes the importance of optimizing management of metabolic syndrome and its components in LTRs and highlights the cardioprotective potential for the newer diabetes medications (e.g., sodium glucose transporter-2 inhibitors) in this high-risk population. Tailoring the multidisciplinary management of cardiac diseases in LTRs to the cardiometabolic risk profile of the individual patient is critical. The review also outlines numerous knowledge gaps to pave the road for future research in this sphere with the ultimate goal of improving clinical outcomes.

12 January 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
DSDeirdre Sawinski
Deirdre Sawinski
JLJennifer C. Lai
Jennifer C. Lai
SPSean Pinney
Sean Pinney
AGAlice L. Gray
Alice L. Gray
AJAnnette M Jackson
Annette M Jackson
EPElizabeth Pomfret
Elizabeth Pomfret
Solid organ transplantation provides the best treatment for end-stage organ failure, but significant sex-based disparities in transplant access exist. On June 25, 2021, a virtual multidisciplinary conference was convened to address sex-based disparities in transplantation. Common themes contributing to sex-based disparities were noted across kidney, liver, heart, and lung transplantation, specifically the existence of barriers to referral and wait listing for women, the pitfalls of using serum creatinine, the issue of donor/recipient size mismatch, approaches to frailty and a higher prevalence of allosensitization among women. In addition, actionable solutions to improve access to transplantation were identified, including alterations to the current allocation system, surgical interventions on donor organs, and the incorporation of objective frailty metrics into the evaluation process. Key knowledge gaps and high-priority areas for future investigation were also discussed.

26 March 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
PHPhilip F. Halloran
Philip F. Halloran
KMKatelynn Madill-Thomsen
Katelynn Madill-Thomsen
AAArezu Z. Aliabadi-Zuckermann
Arezu Z. Aliabadi-Zuckermann
MCMartin Cadeiras
Martin Cadeiras
MCMarisa G. Crespo-Leiro
Marisa G. Crespo-Leiro
AZAndreas Zuckermann
Andreas Zuckermann
The first-generation Molecular Microscope® (MMDx) system for heart transplant endomyocardial biopsies used expression of rejection-associated transcripts (RATs) to diagnose T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR) but also detected acute injury. However, the ideal system should detect rejection without being influenced by injury, to permit analysis of the relationship between rejection and parenchymal injury. To achieve this, we developed a new rejection classification in an expanded cohort of 3230 biopsies: 1641 from INTERHEART (ClinicalTrials.gov #NCT02670408), plus 1589 service biopsies added to improve the power of the machine learning algorithms. The new system used six rejection classifiers instead of RATs and generated seven rejection archetypes: No Rejection 48%; Minor 24%; TCMR1 2.3%; TCMR2 2.7%; TCMR/Mixed 2.7%; EABMR 3.9%; and FABMR 16%. Using rejection classifiers eliminated cross-reactions with acute injury, permitting separate assessment of rejection and injury. TCMR was associated with severe recent injury and late atrophy-fibrosis and rarely had normal parenchyma. ABMR was better tolerated, seldom producing severe injury, but in later biopsies was often associated with atrophy-fibrosis, indicating long term risk. Graft survival and LVEF were reduced in hearts with TCMR, but also in hearts with severe-recent injury and atrophy-fibrosis, even without rejection. INTERHEART: ClinicalTrials.gov NCT02670408.

4 December 2021 in Clinical Transplantation
Verified
Journal Article
Open access
PDF file
AAAasim Afzal
Aasim Afzal
AAAmit Alam
Amit Alam
JZJohanna van Zyl
Johanna van Zyl
HZHira Zafar
Hira Zafar
JFJoost Felius
Joost Felius
SCSandra A. Carey
Sandra A. Carey
Donor‐derived cell free DNA (dd‐cfDNA) has rapidly become part of rejection surveillance following orthotopic heart transplantation. However, some patients show elevated dd‐cfDNA without clinical evidence of rejection. With the aim to provide a clinical description of this subpopulation, we retrospectively analyzed 35 cardiac transplant recipients at our center who experienced elevated (≥.20%) dd‐cfDNA in the absence of clinical rejection, out of a total 106 recipients who had dd‐cfDNA results available during the first year. The median time to first elevated dd‐cfDNA level was 46 days, and the highest dd‐cfDNA recorded within 1 year was .31% [inter‐quartile range, .23–.45]. Twenty‐two (63%) patients experienced infections (cytomegalovirus (CMV) or other), and 16 (46%) presented with de novo donor‐specific antibodies. Cluster analysis revealed four distinct groups characterized by (a) subclinical rejection with 50% CMV (n = 16), (b) non‐CMV infections and the longest time to first elevated dd‐cfDNA (187 days) (n = 8), (c) right ventricular dysfunction (n = 6), and (d) women who showed the youngest median age (45 years) and highest median dd‐cfDNA (.50%) (n = 5). Continued prospective analysis is needed to determine if these observations warrant changes in patient management to optimize the utilization of this vital non‐invasive graft surveillance tool.